MBRC 201
Alternative Names: MBRC-201Latest Information Update: 17 May 2024
At a glance
- Originator MBrace Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 30 Apr 2024 Preclinical trials in Haematological malignancies in USA (Parenteral) (MBrace Therapeutics pipeline, April 2024)
- 30 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) (MBrace Therapeutics pipeline, April 2024)